No evidence of NRAS mutation in squamous cell anal carcinoma (SCAC). Scientific Reports

Laura Capelli1, Andrea Casadei Gardini2, Emanuela Scarpi3, Giovanni Luca Frassineti2, Luca Saragoni4, Maurizio Puccetti5, Mario Scartozzi6, Massimo Giannini7, Stefano Tamberi8, Jody Corbelli8 & Paola Ulivi1 1Biosciences Laboratory, Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST) IRCCS, Meldola, Italy 2Department of Medical Oncology, Istituto Scientifico Romagnolo per lo Studio e la Cura […]

Impact of CYP19A1 and ESR1 variants on early-onset side effects during combined endocrine therapy in the TEXT trial. Breast Cancer Research

Harriet Johansson1, Kathryn P. Gray2, Olivia Pagani3,4,5, Meredith M. Regan6, Giuseppe Viale7, Valentina Aristarco1, Debora Macis1, Antonella Puccio1, Susanne Roux8, Rudolf Maibach8, Marco Colleoni1, Manuela Rabaglio9, Karen N. Price9,10, Alan S. Coates11, Richard D. Gelber12, Aron Goldhirsch13, Roswitha Kammler14, Bernardo Bonanni1†, Barbara A. Walley15,16† and the TEXT principal investigators 1Division of Cancer Prevention and Genetics, […]

RAS testing practices and RAS mutation prevalence among patients with metastatic colorectal cancer: results from a Europe-wide survey of pathology centres. BMC Cancer

Annemarie Boleij1, Véronique Tack2, Aliki Taylor3, George Kafatos3, Sophie Jenkins-Anderson4, Lien Tembuyser2, Els Dequeker2 and J. Han van Krieken1 1Department of Pathology, Radboud University Medical Centre 2Department of Public Health and Primary Care, University of Leuven 3Centre for Observational Research, Amgen Ltd 4Adelphi Research (Global) Abstract: Background Treatment options for patients with metastatic colorectal cancer […]

logo Diatech Pharmacogenetics

Subscribe to Our Newsletter